1154 / 1578
/
Medical Oncology
Radio-Oncology
Cetuximab
Panatimumab
Bevacizumab
Trastuzumab
Ipilimumab
Pembrolizumab
Nivolumab
Afatinib
Lapatinib
Axatinib
Sorafenib
Sunitinib
Pazopanib
Vandetanib
….
Colorectal
Breast
Pancreas
NSCLC
Glioblastoma
Renal cell cancer
GIST
Thyroid
Head & Neck
….
Cetuximab
Head & Neck
Approved targeted drugs
Unsuccessful
Cetuximab
RCHT Head & Neck
Rectal cancer
Esophageal cancer
NSCLC
Bevacizumab
Glioblastoma
Ø
Combining targeted drugs & conventionally fractionated
radio(chemo)therapy has been an unsuccessful strategy
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
5
/
Adoption of SBRT in the (oligo)-
metastatic situation
Ø
SBRT for oligo-metastasis has become a standard
of care
Adoption of SBRT for
oligometastasis
Overall
Western
Europe
61% 76%
International Survey of 1007 Radiation Oncologists
Lewis American Journal of Clinical Oncology 2015
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
6